Acrivon Therapeutics, Inc. (ACRV) Tops Q4 EPS by 72c

Acrivon Therapeutics, Inc. (NASDAQ: ACRV) reported Q4 EPS of ($0.49), $0.72 better than the analyst estimate of ($1.21).

For earnings history and earnings-related data on Acrivon Therapeutics, Inc. (ACRV) click here.

You May Also Be Interested In

• Anthropic Signs $35b Cloud Deal With Lambda In Texas: WSJ
• Verizon readies Gulf Coast network ahead of Tropical Storm Edouard
• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short